Core Viewpoint - The Tempus AI class action lawsuit alleges that the company and its executives made misleading statements and failed to disclose critical information regarding its financial practices and operations, leading to significant stock price declines [3][4]. Group 1: Allegations Against Tempus AI - The lawsuit claims that Tempus AI inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded [3]. - It is alleged that the credibility of Tempus AI's joint venture with SoftBank was compromised, suggesting potential "round-tripping" of capital to artificially inflate revenue [3]. - The business model of Ambry Genetics, acquired by Tempus AI, is said to be based on aggressive and potentially unethical billing practices, raising concerns about sustainability [3]. - AstraZeneca reportedly reduced its financial commitments to Tempus AI through a questionable "pass-through payment" arrangement, indicating operational weaknesses [3]. - These issues collectively reveal vulnerabilities in Tempus AI's core operations and revenue prospects [3]. Group 2: Impact of Allegations - Following a research report from Spruce Point Capital Management that highlighted numerous concerns regarding Tempus AI's management and financial reporting, the company's stock price fell by over 19% [4]. Group 3: Class Action Process - Investors who purchased Tempus AI common stock during the specified class period can seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [5]. - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect the ability to share in any potential recovery [5]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [6]. - The firm has been recognized for its significant recoveries in securities class action cases, including the largest recovery in history of $7.2 billion in the Enron case [6].

Core Points - GameStop is involved in a class-action lawsuit regarding an alleged privacy breach, where it is accused of sharing customers' personal information without consent [1][2] - The settlement amounts to $4.5 million, with affected customers eligible for a cash payment of up to $5 or a voucher worth approximately $10 [2] - Customers who purchased a game from GameStop's website between August 18, 2020, and April 17, 2025, and have a public Facebook account can qualify for compensation [3] Settlement Details - Eligible customers must submit a claim by August 15, providing personal information and proof of Facebook account ownership [4] - GameStop denies any wrongdoing but has opted for the settlement to avoid further legal uncertainties and costs [6]

Palantir (NASDAQ: PLTR) has been one of the top-performing stocks in the S&P 500 this year, frequently hovering around the number one spot with impressive year-to-date gains of 73.80%. However, another tech stock has been posting similar numbers, and it may surprise you.Roblox (NYSE: RBLX) stock has surged 73.95% year-to-date, currently trading at $100.65 after a solid 12% rally over the past month alone.​​That said, both Palantir and Roblox dipped over 4% following Monday’s trading session, hinting at some ...

Eastman Chemical (NYSE: EMN ) is a specialty chemicals and materials innovation company that operates in four segments: Advanced Materials, Additives and Functional Products, Chemical Intermediates, and Fibers. It is headquartered in Tennessee but has plants in twelve countries and competesLaura Starks is the founder and CEO of Starks Energy Economics, LLC (since 2007). She has a degree in chemical engineering and an MBA with a concentration in finance which she has used for many years to invest personally ...

HAMILTON, Bermuda, July 2, 2025 /PRNewswire/ -- Borr Drilling Limited (NYSE: BORR) is pleased to announce new contract commitments for four of its premium jack-up rigs, bringing the total number of contracted rigs to 23 out of its fleet of 24.The new awards have a combined duration of approximately 1,300 days, including fixed priced options, and an estimated contract revenue of more than $129 million1. In line with our strategy to optimize near term fleet utilization, these new commitments provide strengthe ...

As of 2025, I've got over 10 years of researching companies. In total, throughout my investing life, I estimate that I researched (in depth) well over 1000 companies, from commodities like oil, natural gas, gold and copper to tech like Google or Nokia and many emerging market stocks, which I believe could help me provide useful content for readers. After writing my own blog for about 3 years, I decided to switch to a value investing-focused YouTube channel, where I researched hundreds of different companies ...

It's been nearly six months since I issued a Buy rating for Extreme Networks, Inc. (NASDAQ: EXTR ), and I'm sticking with the recommendation even though the stock has been very volatile in the periodI’m Emmanuel Onwusah—a financial analyst, writer, and recovering engineer. I hold FMVA® and BIDA® certifications from the Corporate Finance Institute, and I spend most of my time creating pitch decks, building models, analyzing companies, and trying to make sense of where value meets narrative. My background is ...

Moretus Research delivers state-of-the-art, buy-side quality equity research for serious investors seeking clarity, conviction, and alpha. Focused on U.S. public markets, Moretus applies a structured, repeatable framework to identify companies with durable business models, mispriced cash flow potential, and intelligent capital allocation. Built on institutional standards, Moretus Research combines rigorous fundamental analysis with a high-signal, judgment-driven process—eschewing noise, narrative, and overl ...

CVRx (NASDAQ: CVRX ) is a pioneering medical device company to treat advanced heart failure through its FDA-approved therapy. While the company remains unprofitable through heavy investment in US sales and support infrastructure, the company hasI am currently working as an investment analyst at a family office. My specialty is identifying high-quality and/or severely mispriced investment ideas. I believe that a great investment idea would "jump" at you intuitively and it comes in buying great companies at g ...

LONDON, July 02, 2025 (GLOBE NEWSWIRE) -- Quantexa, a global leader in Decision Intelligence (DI) for the public and private sectors, today announced it has been named as a Luminary in Everest Group's Innovation Watch: Generative AI Applications in Financial Crime and Compliance (FCC) report. This prestigious acknowledgment highlights Quantexa's innovative use of generative AI as part of its’ Decision Intelligence Platform, to transform the financial crime and compliance practice. At the center of this reco ...